These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 11941554)

  • 1. Assessing eosinophil count as a marker of immune activation among human immunodeficiency virus-infected persons in sub-Saharan Africa.
    Chorba TL; Nkengasong J; Roels TH; Monga B; Maurice C; Maran M; Djomand G
    Clin Infect Dis; 2002 May; 34(9):1264-6. PubMed ID: 11941554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.
    Breton G; Lewden C; Spire B; Salmon D; Brun-Vézinet F; Duong M; Allavena C; Leport C; Salamon R;
    HIV Med; 2007 Apr; 8(3):164-70. PubMed ID: 17461860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of CD4 T-lymphocyte counts from percent CD4 T-lymphocyte determinations in HIV-1-infected subjects in sub-Saharan Africa.
    Sandström E; Urassa W; Bakari M; Swai A; Mhalu F; Biberfeld G; Pallangyo K
    Int J STD AIDS; 2003 Aug; 14(8):547-51. PubMed ID: 12935385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART.
    Beran O; Holub M; Spála J; Kalanin J; Stanková M
    Acta Virol; 2003; 47(2):121-4. PubMed ID: 14524479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis?
    Bongiovanni M; Gori A; Lepri AC; Antinori A; de Luca A; Pagano G; Chiodera A; Puoti M; Monforte Ad;
    Clin Infect Dis; 2007 Sep; 45(5):650-3. PubMed ID: 17683003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection.
    Eggena MP; Barugahare B; Okello M; Mutyala S; Jones N; Ma Y; Kityo C; Mugyenyi P; Cao H
    J Infect Dis; 2005 Mar; 191(5):694-701. PubMed ID: 15688282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial evaluation of percentage of activated T-lymphocytes in peripheral blood of human immunodeficiency virus infected individuals as a prognostic marker.
    Shakoor Z
    Saudi Med J; 2003 Jun; 24(6):632-6. PubMed ID: 12847593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of opportunistic DNA viral infections by multiplex PCR among HIV infected individuals receiving care at a tertiary care hospital in South India.
    Sachithanandham J; Ramamurthy M; Kannangai R; Daniel HD; Abraham OC; Rupali P; Pulimood SA; Abraham AM; Sridharan G
    Indian J Med Microbiol; 2009; 27(3):210-6. PubMed ID: 19584500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients.
    Morris L; Martin DJ; Bredell H; Nyoka SN; Sacks L; Pendle S; Page-Shipp L; Karp CL; Sterling TR; Quinn TC; Chaisson RE
    J Infect Dis; 2003 Jun; 187(12):1967-71. PubMed ID: 12792875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic herpes simplex virus type-2 infection and HIV viral load.
    Duffus WA; Mermin J; Bunnell R; Byers RH; Odongo G; Ekwaru P; Downing R
    Int J STD AIDS; 2005 Nov; 16(11):733-5. PubMed ID: 16303067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of GBV-C infection in HIV-1 infected patients.
    Canducci F; Uberti Foppa C; Boeri E; Racca S; Gallotta G; Grasso MA; Calori G; Lazzarin A; Clementi M
    J Biol Regul Homeost Agents; 2003; 17(2):191-4. PubMed ID: 14518722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire.
    Kalou M; Sassan-Morokro M; Abouya L; Bile C; Maurice C; Maran M; Tossou O; Roels T; Greenberg AE; Wiktor SZ; Nkengasong JN
    J Med Virol; 2005 Feb; 75(2):202-8. PubMed ID: 15602734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy.
    Siddique MA; Hartman KE; Dragileva E; Dondero M; Gebretsadik T; Shintani A; Peiperl L; Valentine F; Kalams SA
    J Infect Dis; 2006 Sep; 194(5):661-5. PubMed ID: 16897665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
    Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
    J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
    Miro JM; Lopez JC; Podzamczer D; Peña JM; Alberdi JC; Martínez E; Domingo P; Cosin J; Claramonte X; Arribas JR; Santín M; Ribera E;
    Clin Infect Dis; 2006 Jul; 43(1):79-89. PubMed ID: 16758422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.